CCT6A facilitates lung adenocarcinoma progression and glycolysis via STAT1/HK2 axis

Background Chaperonin Containing TCP1 Subunit 6 A (CCT6A) is a prominent protein involved in the folding and stabilization of newly synthesized proteins. However, its roles and underlying mechanisms in lung adenocarcinoma (LUAD), one of the most aggressive cancers, remain elusive. Methods Our study utilized in vitro cell phenotype experiments to assess CCT6A’s impact on the proliferation and invasion capabilities of LUAD cell lines. To delve into CCT6A’s intrinsic mechanisms affecting glycolysis and proliferation in lung adenocarcinoma, we employed transcriptomic sequencing and liquid chromatography-mass spectrometry analysis. Co-immunoprecipitation (Co-IP) and chromatin immunoprecipitation (CHIP) assays were also conducted to substantiate the mechanism. Results CCT6A was found to be significantly overexpressed in LUAD and associated with a poorer prognosis. The silencing of CCT6A inhibited the proliferation and migration of LUAD cells and elevated apoptosis rates. Mechanistically, CCT6A interacted with STAT1 protein, forming a complex that enhances the stability of STAT1 by protecting it from ubiquitin-mediated degradation. This, in turn, facilitated the transcription of hexokinase 2 (HK2), a critical enzyme in aerobic glycolysis, thereby stimulating LUAD’s aerobic glycolysis and progression. Conclusion Our findings reveal that the CCT6A/STAT1/HK2 axis orchestrated a reprogramming of glucose metabolism and thus promoted LUAD progression. These insights position CCT6A as a promising candidate for therapeutic intervention in LUAD treatment. Supplementary Information The online version contains supplementary material available at 10.1186/s12967-024-05284-7.


Introduction
Lung cancer stands as the second most common cancer worldwide and the foremost cause of cancer mortality [1].Approximately 85% of diagnosed lung cancers are non-small cell lung cancers, and lung adenocarcinoma (LUAD) is the most common subtype of them [2].Due to its high malignancy and the limited effectiveness of chemotherapy, patients with LUAD faced grim survival outcomes.The advent of targeted therapies has markedly prolonged the survival of patients with mutations in key driver genes such as EGFR, ALK, MET, ROS1, RET, and HER2 [3].Nevertheless, a significant fraction of LUAD patients do not possess these mutations, highlighting the critical need for identifying new actionable driver genes [4][5][6].
Abnormal metabolism is a hallmark feature of cells during tumor initiation and progression [19].The phenomenon of active glycolysis in the presence of ample oxygen is referred to as "aerobic glycolysis" [20].Aerobic glycolysis enables swift ATP generation to cater to the heightened demands of cancer cells during rapid growth and proliferation.Additionally, it supplies essential intermediate metabolites crucial for nucleotide, amino acid, and lipid synthesis [21].Numerous studies have substantiated the correlation between cancer and various glycolytic enzymes [22][23][24][25].Hexokinase2 (HK2) catalyzes the conversion of glucose to glucose-6-phosphate, a key ratelimiting step in glycolysis and energy production [26,27].Its expression is significantly upregulated in cancer cells compared to normal cells, and it is closely associated with rapid proliferation and drug resistance in diverse cancer types [28][29][30][31].
Our study revealed that CCT6A facilitated the stabilization of the STAT1 protein, which in turn transcriptionally upregulates HK expression, thereby enhancing aerobic glycolysis and promoting LUAD cell progression.This suggests that the metabolic reprogramming induced by CCT6A could advance LUAD progression, making the CCT6A/STAT1/HK2 axis a promising target for therapeutic intervention.

Bioinformatic analysis and clinical specimens
Public mRNA sequencing data and corresponding survival data of LUAD were downloaded from TCGA (https://cancergenome.nih.gov/) and GEO (https://www.ncbi.nlm.nih.gov/).We obtained the LUAD tissue microarray (TMA) (AF-LucSur2202) from Hunan AiFang Biological and the final follow-up time was September 2022.A total of 80 LUAD tissue specimens and 80 paired normal tissue specimens were collected to compose the TMA.Immunohistochemistry (IHC) was performed with an anti-CCT6A antibody (AiFang, China, AF01764) and H-score was calculated by the formula: H-score = expressing intensity × expressing percentage.This study was approved by the Institutional Review Board of the First Affiliated Hospital of Nanjing Medical University (2023-SRFA-076).

Transfection
Specifically synthesized siRNA and shRNA were provided from Shanghai Genechem company (sequence shown in Table S1).Full length CCT6A and HK2 cDNA was cloned into the pLVX-FLAG-puro vector for CCT6A and HK2 overexpression.Transfection was performed utilizing Lipo8000™ Transfection Reagent (Beyotime, China) according to the manufacturer's protocol.The stably transfected cells were selected out with puromycin at a density of 5 µg/ml.

RNA extraction and quantitative real-time PCR (qRT-PCR)
Total RNA lysis was obtained using an RNA extraction kit (Beyotime, R0027, China).Reverse transcription was performed using HiScript III RT SuperMix for qPCR (+ gDNA wiper) (Vazyme, R323-01, China) with 1 µg of total RNA.Amplification of synthesized cDNA was performed using ChamQ SYBR qPCR Master Mix (High ROX Premixed) (Vazyme, Q341-02, China).β-actin was used as an internal control to normalize gene expressions.The relative RNA levels of the indicated genes were calculated using the 2 −ΔΔCT method.Each experiment was performed in triplicate.The primers used were also shown in Table S1.

Cell proliferation and apoptosis assay
For the colony formation assay, cells were seeded in 6-well plates at a density of 1500 cells per well.After 7-10 days, cells were washed with PBS twice, fixed with 4% paraformaldehyde for 20 min, and then stained with crystal violet (Beyotime, C0121, China) for 20 min.Colonies were photographed and counted with ImageJ.
For the CCK-8 assay, cells were seeded in 96-well plates at a density of 2500 cells per well.Optical density (OD) values were measured at 450 nm with a CCK-8 assay (Beyotime, C0038, China) every 24 h for 96 h.
For cell apoptosis measurement, 1 × 10 5 cells were collected and washed with PBS twice.Then, the cells were labeled with the Annexin V-FITC/PI apoptosis detection kit (Beyotime, C1062M, China) following the instructions.The samples were then analyzed with fluorescence activated cell sorter (FACS).Annexin V(+)/PI(−) represented early apoptosis while Annexin V(+)/PI(+) denoted late apoptosis.

Cell migration assays
3 × 10 4 cells in 300 µl of serum-free medium were added to the upper chamber while medium with 10% FBS was added to the lower chamber.After 24 h incubation, migrating cells were fixed with 4% paraformaldehyde for 20 min and stained with crystal violet for 20 min.Then, the cells were counted at 10×magnification.Subsequentially, cells were seeded in twelve-well plates for the wound healing assay.Scratches were made using a 1000 µl pipette tip after adherence and 95% coverage.After 48 h incubation, bright-field images of randomly selected views were captured at 10×magnification.The cell migration rate was calculated using the formula: [1-(remained wound area/initial wounded area)×100%].

In vivo xenograft model
Animal studies were approved by the Laboratory Animal Welfare and Ethics Committee of the First Affiliated Hospital of Nanjing Medical University.About 1 × 10 6 cells were suspended in 100 µl PBS and then injected subcutaneously into BALB/c nude mice (5 weeks old, Gempharmatech, D000521).Every 4-5 days, tumor volume was measured and calculated using the following equation: (longer axes×shorter axes^2)/2.Tumor weight was calculated after executed and then fixed in 4% formalin for IHC analysis.All animal experiments were approved by the Committee on the Ethics of Animal Experiments of the Nanjing Medical University (IACUC-2,310,034).

Glucose consumption, lactic acid production, and intracellular ATP detection
Glucose consumption and lactic acid production were measured using fluorescence-based assay kits as described by the manufacturer's instructions (Nanjing Jiancheng Bioengineering Institute, F006-1-1, A019-2-1, China) respectively.Intracellular ATP levels were determined using an ATP luminometric assay kit (Beyotime, S0027, China) according to the manufacturer protocol.The total amounts of glucose consumption, lactate acid production, and intracellular ATP were normalized to protein concentration.

RNA-sequencing (RNA-seq)
RNA sequencing was conducted using the Illumina HiSeq TM 2500 system by BGI Genomics (Beijing, China).Initially, mRNA was isolated and enriched with oligo(dT)-attached magnetic beads.The mRNA was then fragmented, and cDNA synthesis followed.Subsequently, PCR was performed and the PCR products were circularized to form single-stranded circular DNA molecules.These circular DNA molecules were replicated via rolling cycle amplification to generate DNA nanoballs (DNBs), which were loaded into nanoarrays and sequenced using the combinatorial Probe-Anchor Synthesis (cPAS) method.

Co-immunoprecipitation assays (Co-IP)
Total protein was obtained using RIPA lysis buffer (Beyotime, P0013B, China) containing protease inhibitor cocktails (Beyotime, ST506, China).Protein lysates were then incubated overnight with primary antibodies or IgG and Protein A/G PLUS-Agarose (Santa Curz, sc-2003, USA).The beads were then washed with PBS, and resuspend in SDS-PAGE buffer.After centrifuged, the supernatant of the resuspended protein was detected using WB.For ubiquitination assays, A549 cells were treated with MG132 (10µM, 8 h), and the cell lysates were immunoprecipitated by STAT1 antibody, and STAT1 ubiquitination was analyzed by WB with Poly-ub antibody.

Mass spectrometry analysis
Co-immunoprecipitated proteins were visualized using a Coomassie Blue Staining Kit (Beyotime, China).The protein bands of interest were meticulously excised from the gel and subsequently digested.These peptides were analyzed with nanoLC-MS/MS (Sangon Biotech, Shanghai, China), using an Orbitrap Fusion mass spectrometer.The mass spectrometry-generated raw spectral data were then processed and analyzed employing PEAKS Studio 8.5 software for detailed characterization.

Immunofluorescence assay
The immunofluorescence assay followed the directions of Immunol Fluorescence Staining Kit (Beyotime, China).Cells were fixed by 4% paraformaldehyde for 20 min, permeabilized for 10 min by 0.5% Triton X-100 and blocked for 1 h with blocking buffer.Subsequently, cells were incubated with primary antibodies overnight at 4 °C and followed by incubation with fluorescent secondary antibodies for 2 h in the dark at room temperature.DAPI was used for nuclear staining.Fixed cells were then photographed to show the distribution of proteins at a 40× magnification.

Chromatin immunoprecipitation (ChIP) assay
A ChIP assay was performed using a ChIP Assay Kit with Protein A/G Magnetic Beads (Beyotime, P2080S, China) according to the manufacturer's protocol.Briefly,1*10 7 cells were fixed with 1% paraformaldehyde for 10 min and scraped off.Then, cell pellets were collected after centrifugation and resuspended in 1 ml lysis buffer and sonicated.The lysates were centrifugation to remove cell debris, and the chromatin solutions were diluted.Chromatin fragments were immunoprecipitated with primary antibody or IgG overnight at 4 °C.Then, Protein A/G Magnetic Beads were added to the lysate and incubated at 4 °C for 2 h.The DNA fragments were purified with a DNA Purification Kit (Beyotime, D0033, China) after reverse cross-linking at 65 °C for 4 h.The immunoprecipitated DNA was analyzed by qPCR normalized to IgG control.

Luciferase reporter assay
The reporter plasmids containing the HK2 promoter site2, as well as matched mutant sequences ( C A A G T C C C T T C), were designed by GeneChem (Shanghai, China).Briefly, 293T cells were transfected with the indicated plasmids.48 h after transfection, the firefly luciferase activity was calculated and analyzed.

Statistics
Survival analysis was performed using univariate and multivariate Cox regression analyses, and survival curves were plotted with the Kaplan-Meier method.Comparisons between groups were conducted using Student's t test or one-way ANOVA.All in vitro experiments were performed in triplicate and repeated three times.Statistical analysis was performed using Graph-Pad Prism 9.0.0 and SPSS (version 20.0).p < 0.05 was considered statistically significant, and the data are presented as means ± standard deviation.*P < 0.05; **P < 0.01; ***P < 0.001.

CCT6A was highly expressed in LUAD and correlated with worse prognosis
To explore the roles of CCT family genes in LUAD, we conducted differential expression and Cox proportional hazards analyses using TCGA database.Among the nine investigated genes, all except CCT6B showed higher expression levels in LUAD tissues than in normal tissues (Fig. 1A) and were correlated with poorer prognosis of LUAD patients (Fig. 1B).Further, multivariate Cox analysis indicated CCT6A as an independent prognostic factor for LUAD, linked to worse survival outcomes (Fig. 1C).
Based on TCGA-LUAD, the expression of CCT6A in LUAD tissues was significantly elevated compared to that in normal tissues, indicating its high specificity and sensitivity in distinguishing LUAD (Fig. 1D).Data from GSE68465 demonstrated that patients with lower CCT6A expression had improved overall survival (OS) and progression-free survival (PFS) than those with higher expression levels (Fig. 1E).CCT6A expression also increased in more advanced TNM stages (Figure S1).A total of 80 pairs of LUAD tumors and adjacent normal tissues were collected, with their clinical information summarized in Table 1.Immunohistochemistry (IHC) staining showed a significant increase in CCT6A protein levels in LUAD tissues versus normal tissues (Fig. 1F-G), and patients with higher H-scores experienced significantly worse prognoses (Fig. 1H).Western blot (WB) and PCR analyses confirmed higher CCT6A expression in LUAD cell lines compared to that in normal pulmonary epithelial cell line (Fig. 1I-J).

CCT6A knockdown impaired LUAD proliferation both in vitro and in vivo
In the A549 and PC9 cell lines, CCT6A expression was either decreased through transfection with short hairpin RNAs (shRNAs) or increased via plasmid transfection (Fig. 1K).Notably, CCT6A silencing suppressed both colony formation and proliferation in LUAD cell lines (Fig. 2A-B).This intervention also resulted in a substantial increase in the proportion of apoptotic cells (Fig. 2C).Further analysis using scratch wound healing and transwell assays demonstrated that CCT6A silencing markedly reduced LUAD cell migration compared to control groups (Fig. 2D-E).The effect of CCT6A on LUAD's tumorigenic potential was additionally assessed in vivo through the subcutaneous injection of A549 cells into BALB/c-nude mice (Fig. 2F), which showed that CCT6A knockdown significantly slowed tumor volume and weight growth (Fig. 2G-H).Moreover, CCT6A knockdown was observed to decrease the Ki-67 index, indicating a reduction in tumor cell proliferation (Fig. 2I).
Conversely, overexpressing CCT6A facilitates LUAD cell growth, proliferation, and migration while reducing the proportion of apoptotic cells compared to the control group (Figure S2A-E).This was accompanied by increased tumorigenicity in vivo and a higher Ki-67 index (Figure S2F-I).These findings collectively confirm CCT6A's critical role in enhancing tumor growth and proliferation, both in vitro and in vivo.

CCT6A enhanced aerobic glycolysis in LUAD cells
To unravel the underlying mechanism by which CCT6A promotes LUAD cell proliferation and migration, we conducted pathway enrichment analysis using the TCGA database.Remarkably, the glycolysis pathway was enriched in the CCT6A-high group, as indicated by analyses using both HALLMARK (Fig. 3A-B) and KEGG (Fig. 3C-D) gene sets.Further exploration into CCT6A's impact on glucose metabolism revealed that CCT6A knockdown led to decreases in lactate production, glucose consumption, and intracellular ATP level in A549 and PC9 cells, while CCT6A overexpression produced the opposite effects (Fig. 3E-G).Analysis of proton efflux rate (PER), which reflects extracellular acidification rate, provided additional evidence that CCT6A silencing diminished the glycolytic capacity of LUAD cells (Fig. 3H-I).Conversely, CCT6A overexpression enhanced this capacity (Fig. 3J-K).

CCT6A orchestrated the oncogenic and glycolytic functions in LUAD through HK2
To investigate the mechanism through which CCT6A facilitates the progression and glycolysis in LUAD cell lines, we performed RNA sequencing (RNA-seq) analysis on A549 cells with CCT6A knockdown.Totally, 851 differentially expressed genes (DEGs) were identified (Fig. 4A), including five associated with glycolysis (Fig. 4B).Among these, HK2 was notable for its direct involvement in the glycolytic pathway as a rate-limiting enzyme.HK2 was found to be highly expressed in LUAD tissues compared to normal tissues, and elevated HK2 expression correlated with poorer OS of LUAD patients (Figure S3A-B).CCT6A knockdown led to reduced HK2 protein expression, whereas CCT6A overexpression resulted in increased HK2 levels (Fig. 4C).Besides, the enhancement of colony formation and proliferation in LUAD cell lines induced by CCT6A overexpression were attenuated by HK2 knockdown (Fig. 4D-E).HK2 knockdown also reversed the reduction in apoptosis observed with CCT6A overexpression (Fig. 4F).Scratch wound healing and transwell assay demonstrated that HK2 knockdown prevented the LUAD cell migration enhancement induced by CCT6A overexpression (Fig. 4G-H).Moreover, HK2 overexpression restored the compromised in vivo tumorigenesis capacity associated with CCT6A silencing (Fig. 4I-L).
Following HK2 knockdown, lactate production, glucose consumption, and intracellular ATP level significantly decreased in A549 and PC9 cells that had undergone CCT6A overexpression (Fig. 5A-C).Additionally, the glycolytic capacity in these cells was diminished with HK2 silencing (Fig. 5D-E).

CCT6A enhanced the protein stability of STAT1 via suppressing ubiquitination
Given established role of the CCT family in protein binding and stabilization, we aimed to explore whether CCT6A could enhance HK2 expression through this mechanism.Interestingly, CCT6A was not found to directly interact with HK2 (Fig. 6A), prompting us to consider that CCT6A might instead assist in the stabilization of a transcription factor, thereby facilitating its activity and leading to an increase in HK2 expression.
To investigate this, mass spectrometry (MS) analysis was performed to identify transcription factors interacting with CCT6A (Fig. 6B).STAT1 emerged as a significant candidate, exhibiting higher expression levels in LUAD cells and correlating with shorter survival in LUAD patients (Fig. 6C-E).The protein levels of STAT1 were observed to decrease following CCT6A knockdown and increase upon CCT6A overexpression (Fig. 6F).Through co-immunoprecipitation (co-IP), we uncovered a binding interaction between CCT6A and STAT1 (Fig. 6G-H), which was further corroborated by confocal fluorescence microscopy demonstrating their co-localization in the cytoplasm (Fig. 6I).Notably, STAT1 expression did not exhibit a linear correlation with CCT6A expression (Figure S3C) and did not significantly change with CCT6A modulation (Figure S3D), indicating that CCT6A influences STAT1 post-transcriptionally.Ubiquitination is a prevalent pathway for protein degradation, prompting us to investigate CCT6A's impact on the ubiquitination of STAT1 protein.Silencing CCT6A was observed to increase the ubiquitin-bound fraction of STAT1, suggesting enhanced ubiquitin-mediated degradation.Conversely, overexpression of CCT6A produced opposing results (Fig. 6J).Additionally, we assessed the protein levels of STAT1 in LUAD cells with cycloheximide (CHX), a protein synthesis inhibitor.Consistent with expectations, CCT6A knockdown hastened the degradation of STAT1 (Fig. 6K) while overexpression of CCT6A decelerated this process (Fig. 6L).These findings suggested that CCT6A might augment the stability of STAT1 by diminishing its ubiquitination.We also explored whether CCT6A's regulation of STAT1 involves ubiquitin E3 ligases.TRIM21 was confirmed to act as a ubiquitin E3 ligase to ubiquitinate STAT1.TRIM21 still downregulated STAT1 regardless of whether CCT6A was knocked down or overexpressed (Figure S3E), indicating that CCT6A's regulatory effect on STAT1 is not mediated through TRIM21.Furthermore, CCT6A did not alter the expression of TRIM21 (Figure S3F) nor was it able to recruit TRIM21 to STAT1 (Figure S3G).These results suggested that CCT6A modulates STAT1 stability in a manner that is independent of ubiquitin E3 ligase activity.

STAT1 facilitated the transcription of HK2
Then, we sought to ascertain whether STAT1 could promote the transcription of HK2.Initially, we observed a correlation between the two mRNA levels (Fig. 7A).Upon silencing STAT1, both HK2 protein and mRNA levels decreased in LUAD cell lines (Fig. 7B-C).Employing online bioinformatics predictive tools (JASPAR, http://jaspar.genereg.net/),we identified two potential STAT1 binding sites within the promoter region of the HK2 gene (Fig. 7D).The binding relationship between STAT1 and the HK2 promoter was subsequently validated through a ChIP assay, affirming site2 as the functional binding site (Fig. 7E-F).To assess the specificity of this interaction, we mutated the HK2 promoter at site2, which significantly reduced STAT1-dependent transcriptional activation (Fig. 7G).
Collectively, CCT6A interacts with and stabilizes STAT1, inhibiting its ubiquitination degradation, and subsequently indirectly upregulates HK2 expression through STAT1's transcriptional activity.This chain of events augments glycolysis, proliferation, and migration in LUAD cells.

Discussion
The eukaryotic group II chaperonin CCT has been established to play important roles in protein folding [32,33].In the context of cancers, CCT is implicated in prooncogenic activities through their assistance in the folding of numerous oncogenes [34].In this study, we aimed to elucidate the impact of CCT proteins on the progression of LUAD.Among the DEGs, CCT6A was identified as the only independent prognostic marker.It exhibited high expression levels in both LUAD cell lines and clinical tissues, with elevated expression correlating with a poorer Overall Survival (OS) and Progression-Free Survival (PFS) in LUAD patients.Silencing of CCT6A not only hindered the proliferation of LUAD cells but also induced apoptosis.Additionally, we validated the tumorigenic role of CCT6A in in vivo models.Pathway analysis and subsequent research into metabolism revealed that CCT6A enhances aerobic glycolysis, which in turn supports LUAD cell proliferation and migration.
Aerobic glycolysis, characterized by enhanced glucose uptake, and ATP and lactate production in conditions of sufficient oxygen, is critical for cancer cell proliferation, migration and resistance to treatment.Aerobic glycolysis accounts for up to 50-70% of total ATP supply in various tumors, despite its relative lower efficiency in ATP production [35].The metabolic intermediates produced during this process are also crucial for the biosynthesis of biomacromolecules, which support rapid tumor growth.Lactate production also creates an acidic environment that might impair immune surveillance [36].Additionally, heightened aerobic glycolysis might attribute to chemotherapy and tyrosine kinase inhibitor (TKI) resistance in lung cancer [37][38][39].Considering these insights, presents a promising avenue for the development of new therapeutic strategies.
Subsequently, we focused on the downstream molecules of CCT6A that facilitate aerobic glycolysis.Through transcriptome sequencing analysis, we observed a marked decrease in the expression of hexokinase 2 (HK2), a pivotal rate-limiting enzyme, following the silencing of CCT6A.Hexokinases serve to catalyze the transformation of glucose into glucose-6-phosphate, thus initiating aerobic glycolysis.Among its isoforms-HK1, HK2, HK3, and HK4-HK2 stands out as the most effective in promoting aerobic glycolysis [40].Previous research has illuminated its association with voltagedependent anion-selective channel protein 1 (VDAC1) located in the mitochondrial outer membrane.This interaction leads to increased ATP production and reduced apoptosis by activating enzymes related to ATP synthesis [41].Notably, HK2 expression is significantly higher in cancer cells than in normal cells, correlating with accelerated proliferation and enhanced resistance to drugs through metabolic reprogramming across various cancer types [28][29][30][31].The expression of HK2 is regulated by various signaling pathways, including β-catenin/c-Myc and PI3K/Akt axes [42,43], as well as transcription factors like HIF-1 and STAT3 [28,44].Our investigation additionally reveals that STAT1 plays a role in the transcriptional regulation of HK2, further delineating the complex network of molecular interactions driving cancer metabolism.
Despite these findings, the study has certain limitations.Given that CCT complex helps folding nascent proteins to their functional conformation, representing the binding between CCT6A and nascent STAT1 protein was challenging, and more advanced technique was required to solve this problem.Additionally, the in vivo xenograft experiment had a relatively small sample size, and the glycolysis levels in animal tumors were not measured.

Conclusion
In summary, our research established that CCT6A facilitated glycolysis, proliferation, and migration in LUAD.It enhanced the stability of the STAT1 protein, which in turn promoted the transcription of HK2.Consequently, the CCT6A/STAT1/HK2 axis emerged as a promising therapeutic target for LUAD.

Fig. 1
Fig. 1 CCT6A was highly expressed in LUAD and negatively correlated with the prognosis.(A) Heatmap of the CCT family gene expression in LUAD based on TCGA.(B) Univariate Cox analysis of the prognosis-related CCT family genes based on TCGA.(C) Multivariate Cox analysis of the prognosis-related CCT family genes based on TCGA.(D) Unpaired (left) and paired (middle) t tests of CCT6A expression between LUAD and normal tissues and ROC curve showing the sensitivity and specificity to predict the occurrence of LUAD (right) based on TCGA.(E) Kaplan Meier plots showing the significant difference of OS (left) and PFS (right) in LUAD patients between the CCT6A-high and CCT6A-low samples based on GSE68465.(F) Representative IHC plots of tumor and paired normal tissues (20×magnification).Scale bars = 200 μm.(G) Paired t tests of the H-score between tumor and normal tissues.(H) Kaplan Meier plots showing the significant difference of OS in LUAD patients with CCT6A-high and CCT6A-low tissues.(I) CCT6A protein expression in normal lung epithelial cell line and different LUAD cell lines.(J) CCT6A mRNA expression in normal lung epithelial cell line and different LUAD cell lines.(K) The transfection efficiency of shRNAs and plasmid in A549 and PC9 cell lines

Fig. 2
Fig. 2 Loss of CCT6A inhibits the proliferation of LUAD in vitro and in vivo (A-B) Colony formation assays and growth curves (days 1-4) represented the proliferation of A549/PC9 cells infected with sh-NC or sh-CCT6A.Representative images of the crystal violet staining of cells in a 6-well plate and statistics were shown.(C) CCT6A knockdown resulted in increased apoptosis in LUAD cells.Representative FACS images and statistics based on three independent experiments were shown.(D) Transwell assays were performed to assess the migration of A549/PC9 cells infected with sh-NC or CCT6A-sh-1/2.Cells crossing the membrane were dyed with crystal violet (10×magnification).Scale bars = 100 μm.(E) Migration of A549/PC9 cells with CCT6A knockdown was assessed using wound healing assays.Area coverages were observed at 48 h (10× magnification).Scale bars = 100 μm.(F) Representative images of subcutaneous tumors on the left flank of mice injected with sh-NC or sh-CCT6A A549 cell (n = 5, each group).(G) Tumor growth curves were plotted every 5 days to 25days.(H) The weight of tumors was measured.(I) Representative images of IHC staining for CCT6A and Ki67 proteins (20×magnification).Scale bars = 100 μm.* P < 0.05; ** P < 0.01; *** P < 0.001.Variables are presented as mean ± SD

Table 1
The clinical information of the patients